Genomic instability in multiple myeloma: mechanisms and therapeutic implications
- PMID: 23782016
- DOI: 10.1517/14712598.2013.814637
Genomic instability in multiple myeloma: mechanisms and therapeutic implications
Abstract
Introduction: Clonal plasma cells in multiple myeloma (MM) are typified by their nearly universal aneuploidy and the presence of recurrent chromosomal aberrations reflecting their chromosomal instability. Multiple myeloma is also recognized to be heterogeneous with distinct molecular subgroups. Deep genome sequencing studies have recently revealed an even wider heterogeneity and genomic instability with the identification of a complex mutational landscape and a branching pattern of clonal evolution.
Areas covered: Despite the lack of full understanding of the exact mechanisms driving the genomic instability in MM, recent observations have correlated these abnormalities with impairments in the DNA damage repair machinery as well as epigenetic changes. These mechanisms and the resulting therapeutic implications will be the subject of this review.
Expert opinion: By providing growth advantage of the fittest clone and promoting the acquisition of drug resistance, genomic instability is unarguably beneficial to MM cells, however, it may also well be its Achilles heal by creating exploitable vulnerabilities. As such, targeting presumptive DNA repair defects and other oncogenic addictions represent a promising area of clinical investigation. In particular, by inducing gene or pathway dependencies not present in normal cells, genomic instability can generate targets of contextual synthetic lethality in MM cells.
Similar articles
-
The Role of DNA Repair in Genomic Instability of Multiple Myeloma.Int J Mol Sci. 2022 May 19;23(10):5688. doi: 10.3390/ijms23105688. Int J Mol Sci. 2022. PMID: 35628498 Free PMC article. Review.
-
Decoupling of normal CD40/interleukin-4 immunoglobulin heavy chain switch signal leads to genomic instability in SGH-MM5 and RPMI 8226 multiple myeloma cell lines.Leukemia. 2006 Apr;20(4):715-23. doi: 10.1038/sj.leu.2404099. Leukemia. 2006. PMID: 16453006
-
Genomic Instability in Multiple Myeloma.Trends Cancer. 2020 Oct;6(10):858-873. doi: 10.1016/j.trecan.2020.05.006. Epub 2020 May 30. Trends Cancer. 2020. PMID: 32487486 Review.
-
Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma.Biomed Res Int. 2015;2015:943096. doi: 10.1155/2015/943096. Epub 2015 Oct 22. Biomed Res Int. 2015. PMID: 26579543 Free PMC article. Review.
-
Mechanisms of cadmium induced genomic instability.Mutat Res. 2012 May 1;733(1-2):69-77. doi: 10.1016/j.mrfmmm.2011.09.002. Epub 2011 Sep 17. Mutat Res. 2012. PMID: 21945723 Review.
Cited by
-
Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development.Antibodies (Basel). 2019 May 24;8(2):34. doi: 10.3390/antib8020034. Antibodies (Basel). 2019. PMID: 31544840 Free PMC article. Review.
-
Principal Criteria for Evaluating the Quality, Safety and Efficacy of hMSC-Based Products in Clinical Practice: Current Approaches and Challenges.Pharmaceutics. 2019 Oct 24;11(11):552. doi: 10.3390/pharmaceutics11110552. Pharmaceutics. 2019. PMID: 31652984 Free PMC article. Review.
-
HumCFS: a database of fragile sites in human chromosomes.BMC Genomics. 2019 Apr 18;19(Suppl 9):985. doi: 10.1186/s12864-018-5330-5. BMC Genomics. 2019. PMID: 30999860 Free PMC article.
-
A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy.Oncotarget. 2014 May 15;5(9):2487-98. doi: 10.18632/oncotarget.1740. Oncotarget. 2014. PMID: 24809299 Free PMC article.
-
The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.Oncotarget. 2016 Jul 26;7(30):48732-48752. doi: 10.18632/oncotarget.8982. Oncotarget. 2016. PMID: 27129151 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials